Acrobat Genomics announced the successful completion of Phase I and commencement of expanded research in the DARPA RIDDL program as a prime contractor.1
The RIDDL program aims to rapidly discover and develop novel inhibitors of gene editing technologies to enhance safety and counter misuse.1
Acrobat's platform integrates high-throughput functional screening in human cells with AI to design proteins, using data from millions of measurements in living cells.1
Nicholas Hughes, PhD, Co-founder/CEO, expressed pride in the team's achievements against ambitious milestones.1
The company is a Public Benefit Corporation focused on biosecurity and therapeutics, with peer-reviewed research and funding from NIH, biopharma, and investors.1
Sources:
1. https://www.businesswire.com/news/home/20260429238792/en/Acrobat-Genomics-Advances-to-Next-Phase-of-AI-Powered-Inhibitor-Discovery-Program